Cole Philip, Trichopoulos Dimitrios, Pastides Harris, Starr Thomas, Mandel Jack S
Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, USA.
Regul Toxicol Pharmacol. 2003 Dec;38(3):378-88. doi: 10.1016/j.yrtph.2003.08.002.
2,3,7,8-tetrachlordibenzo-p-doxin (TCDD) would not have been designated as a Group 1 carcinogen by IARC had there not been a change in the criteria used for inclusion in this category. Furthermore, there is no precedent for indicating, as did IARC, that a single chemical acts as a pluripotential carcinogen by modestly increasing human risk for all cancer while not increasing the risk for any single cancer at least moderately. IARC moved TCDD to Group 1 based on mechanistic considerations focusing on the Ah receptor. However, while occupancy of the Ah receptor by TCDD may be necessary for its toxicity, it is not sufficient for toxicity or for potential carcinogenicity. Animal evidence relating TCDD exposure to cancer is much stronger than that for humans. However, the large inter-species variation in the relevant dose-response slopes severely limits generalizations from animals to humans. The epidemiologic studies of occupational exposures, pesticide applicators, and community exposures following industrial accidents, notably Seveso, have generated overall relative risks of all cancer of about 1.0. Only case-control studies of soft-tissue sarcoma and non-Hodgkin's lymphoma, all by the same investigator, reported elevated risk from TCDD exposure. However, these results have not been replicated. The representation that a chemical compound (TCDD) would be a late-stage carcinogen for all types of cancer has no precedent and lacks biological foundation. Virtually all late-stage or promoting carcinogens (e.g., hepatitis-C virus, asbestos, and estrogens) cause a very limited number of forms of cancer. The exposure-response meta-analysis of TCDD and cancer developed by the United States Environmental Protection Agency (USEPA) is seriously compromised by its failure to adequately fit the data. The studies used by the USEPA also likely underestimate TCDD body burdens and may be confounded by smoking and other occupational exposures. Furthermore, the use of a linear dose-response model by the USEPA is scientifically unjustified since the underlying model of TCDD as a human carcinogen is based primarily on its supposed receptor-mediated, non-genotoxic (or promotional) mode of action. There are few examples of an agent being suspected as a human carcinogen for decades and then eventually moving into the category of "known" human carcinogens. In contrast, there are hundreds of compounds that remain for decades on lists of "suspected" human carcinogens despite the lack of confirming evidence. The long-term accumulation of negative, weak, and inconsistent findings suggests that TCDD eventually will be recognized as not carcinogenic for humans.
如果用于确定此类别的标准没有变化,2,3,7,8 - 四氯二苯并 - p - 二恶英(TCDD)就不会被国际癌症研究机构(IARC)指定为1类致癌物。此外,IARC所做的如下表示也没有先例,即单一化学物质通过适度增加人类患所有癌症的风险,但至少不会适度增加患任何单一癌症的风险,从而作为一种多潜能致癌物起作用。IARC基于对芳烃受体(Ah受体)的机制性考虑,将TCDD归为1类。然而,虽然TCDD占据Ah受体可能是其毒性产生所必需的,但这对于毒性或潜在致癌性而言并不充分。将TCDD暴露与癌症相关联的动物证据比人类证据有力得多。然而,相关剂量反应斜率在物种间的巨大差异严重限制了从动物到人类的推断。对职业暴露、农药施用者以及工业事故(尤其是塞韦索事故)后的社区暴露进行的流行病学研究得出,所有癌症的总体相对风险约为1.0。只有同一位研究者开展的关于软组织肉瘤和非霍奇金淋巴瘤的病例对照研究报告称,TCDD暴露会增加风险。然而,这些结果并未得到重复验证。一种化合物(TCDD)会成为所有类型癌症的晚期致癌物这一说法没有先例且缺乏生物学依据。几乎所有晚期或促癌剂(如丙型肝炎病毒、石棉和雌激素)只会引发非常有限的几种癌症。美国环境保护局(USEPA)开展的TCDD与癌症的暴露 - 反应荟萃分析因未能充分拟合数据而受到严重影响。USEPA所使用的研究也可能低估了TCDD的体内负荷,并且可能受到吸烟和其他职业暴露的干扰。此外,USEPA使用线性剂量反应模型在科学上是不合理的,因为TCDD作为人类致癌物的潜在模型主要基于其假定的受体介导的非遗传毒性(或促癌)作用模式。一种物质被怀疑为人类致癌物数十年,然后最终被归入“已知”人类致癌物类别的例子很少。相比之下,尽管缺乏确凿证据,但仍有数百种化合物在“疑似”人类致癌物名单上留存数十年。长期积累的负面、微弱且不一致的研究结果表明,TCDD最终将被认定对人类无致癌性。